Loading...
Loading...
SESN| Name | Value |
|---|---|
| Revenues | 40.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 40.0M |
| Operating Expense | 8.0M |
| Operating I/L | -8.9M |
| Other Income/Expense | 1.3M |
| Interest Income | 1.9M |
| Pretax | -7.6M |
| Income Tax Expense | 7.8M |
| Net Income/Loss | -15.3M |
Sesen Bio, Inc. is a late-stage clinical company specializing in the development and commercialization of targeted fusion protein therapeutics (TFPTs) for cancer treatment. Its lead product, Vicineum, is in Phase III clinical trials for BCG-unresponsive non-muscle invasive bladder cancer, carcinoma in situ of the bladder, and squamous cell carcinoma of the head and neck. Additionally, the company is developing VB6-845d for anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. also has a co-development agreement for an imaging agent with Leiden University Medical Center.
